Sio Gene Therapies Inc.
SIOX · NASDAQ
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $53 | $25 | $47 | $88 |
| G&A Expenses | $18 | $17 | $22 | $39 |
| SG&A Expenses | $18 | $17 | $22 | $39 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $72 | $42 | $69 | $127 |
| Operating Income | -$72 | -$34 | -$68 | -$127 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $2 | -$4 | -$2 |
| Pre-Tax Income | -$72 | -$33 | -$72 | -$129 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$72 | -$32 | -$73 | -$129 |
| % Margin | – | – | – | – |
| EPS | -0.98 | -0.62 | -2.93 | -8.02 |
| % Growth | -58.1% | 78.8% | 63.5% | – |
| EPS Diluted | -0.98 | -0.62 | -2.93 | -8.02 |
| Weighted Avg Shares Out | 73 | 52 | 25 | 16 |
| Weighted Avg Shares Out Dil | 73 | 52 | 25 | 16 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $4 | $8 |
| Depreciation & Amortization | $1 | $2 | $3 | $2 |
| EBITDA | -$71 | -$29 | $0 | -$119 |
| % Margin | – | – | – | – |